Scientific Advisors 

George Tsokos, MD.

Professor of Medicine at Harvard Medical School and on staff at Beth Israel Deaconess Medical Center, Harvard Medical School. He served on the Boards of Directors of the Research for the Lupus Foundation of America and serves as a member of the Scientific Advisory Board of the Alliance for Lupus Research.

Willem van Eden, MD. 

Author of more than 240 scientific papers, among which a 1988 paper in Nature was among the top-100 most cited papers worldwide. He is the Receiving Editor for Cell Stress & Chaperones: Stress and Immunity Section Editor and FEMS Immunol. Med. Microbiol.

John Gordon, PhD. 

Dr. Gordon is a world expert in immune tolerance and the Vice President for the Canadian Society of Immunology. He is a Professor at the School of Medicine at the University of Saskatchewan.

Business Advisors 

Erica Pascal, PhD.

Dr. Erica Pascal is the founder of Ingensity™IP, which specializes in providing IP strategy for life sciences companies including biotech, pharmaceuticals & medical devices. Prior to the creation of Ingensity™ IP, she was a partner at a major global law firm.

Masoud Mokhtarani, MD.

Former CMO to Neurovia and Curzion (Acquired by Horizon), and VP of Clinical development at Hyperion (Acquired by Horizon). Decades of experience designing clinical development plans and moving promising therapeutics through the clinic.

Roxanne Bales

Ms. Bales has over 30 years’ experience in the health science industry, including pharmaceutical and biotechnology development. She worked in Regulatory Affairs at Genentech for 10 years and since 2000 has been working with small biotech/pharma companies in the San Francisco Bay Area and elsewhere to develop innovative therapeutic products.

Michael Spellman, PhD.

Dr. Spellman has over 30 years of biotech drug development experience and has advanced biotherapeutics into the clinic and onto the market. His capabilities in analytics, process development, drug supply, regulatory affairs, and QA/QC, have significantly contributed to the approval of drugs in multiple therapeutic areas. 


151 Charles St. W Suite 199

Kitchener, Ontario

N2G 1H6

479 Jessie Street 

San Francisco, California 


© 2020 by Serenity Bioworks





For our latest company news subscribe below